<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In a clinical trial, 42 patients with abdominal Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) were treated with a combination regimen, code-named <z:chebi fb="4" ids="46274">CVA</z:chebi>, consisting of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (<z:chebi fb="3" ids="3498">CTX</z:chebi>), <z:chebi fb="0" ids="28445">vincristine</z:chebi>, and cystosine <z:chebi fb="0" ids="22601">arabinoside</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>In addition, intrathecal <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (i.t </plain></SENT>
<SENT sid="2" pm="."><plain>MTX) was administered as prophylaxis against subsequent central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>) involvement </plain></SENT>
<SENT sid="3" pm="."><plain>Induced remissions, relapse, and survival were compared with those in a preceding group of 44 patients with abdominal <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> treated with <z:chebi fb="3" ids="3498">CTX</z:chebi> along </plain></SENT>
<SENT sid="4" pm="."><plain>Remission rate did not differ significantly in the two treatment groups, although induced remissions were higher in the <z:chebi fb="4" ids="46274">CVA</z:chebi> plus i.t </plain></SENT>
<SENT sid="5" pm="."><plain>MTX-treated group (94% vs. 83%) </plain></SENT>
<SENT sid="6" pm="."><plain>Remission duration was significantly increases (p less than .05) and <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> relapse significantly reduced (p less than .05) in the group treated with <z:chebi fb="4" ids="46274">CVA</z:chebi> and i.t </plain></SENT>
<SENT sid="7" pm="."><plain>MTX </plain></SENT>
<SENT sid="8" pm="."><plain>The combination therapy was associated with higher early <z:hpo ids='HP_0011420'>deaths</z:hpo> during treatment, which adversely affected the overally survival </plain></SENT>
<SENT sid="9" pm="."><plain>It is suggested that a reduction of the initial chemotherapeutic doses, particularly for patients with extensive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> load, could further improve on the results of this trial </plain></SENT>
</text></document>